JPAC Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee

7.18: Cryoprecipitate Pooled, Leucocyte Depleted

Update notice: Section 7.18.3 - Storage has been updated following the issue of Change Notification 17 - 2013

The pooled component represents a source of concentrated FVIII:C, von Willebrand factor, fibrinogen, FXIII and fibronectin from primary cryoprecipitate components derived from units of fresh frozen plasma. The plasma from which the cryoprecipitate was produced was derived from a previously tested donor (as defined in section 7.3) and contains less than 1 × 106 leucocytes per primary component.

7.18.1: Technical information

  • Donations of whole blood where the bleed time exceeded 15 minutes are not suitable for the production of plasma components for direct clinical use.
     
  • Cryoprecipitate Pooled, Leucocyte Depleted is the cryoglobulin fraction of plasma obtained by thawing and pooling five single cryoprecipitate components or pooling five single cryoprecipitate components immediately after production from thawed fresh frozen plasma.
     
  • Plasma should be selected from male donors or consideration should be given to screening female donors for HLA/HNA antibodies, as a TRALI risk reduction measure.
     
  • For storage, Cryoprecipitate Pooled, Leucocyte Depleted should be rapidly frozen to a core temperature of –25°C or below within 2 hours of preparation.
     
  • Component samples collected for the quality monitoring assessment of FVIII:C should be from an equal mix of group O and non-O donations due to the difference in FVIII levels between ABO blood groups.
     
  • Initial process validation must ensure that for a minimum of 20 tested Cryoprecipitate Pooled, Leucocyte Depleted components a minimum of 75% of those components tested for the parameters shown in Table 7.15 shall meet the specified values.
     
  • Annual process validation is acceptable for quality monitoring purposes, provided that the primary components, Fresh Frozen Plasma, Leucocyte Depleted and/or Cryoprecipitate, Leucocyte Depleted are separately monitored as part of monthly testing. If this is not the case, test monthly 1% or as determined by statistical process control (if ≤10 components produced per month then test every available component), of Cryoprecipitate Pooled, Leucocyte Depleted components. A minimum of 75% of those components tested for the parameters shown in Table 7.15 shall meet the specified values.
     
  • A secure system must be in place to ensure a full audit trail and that the correct identification number is put on the final component pack.
     
  • Cryoprecipitate Pooled, Leucocyte Depleted should be transfused through a 170–200 µm filter.

7.18.2: Labelling

For general guidelines, see section 6.6.

The following shall be included on the component label:

(* = in eye-readable and UKBTS approved barcode format)

  • Cryoprecipitate Pooled, Leucocyte Depleted* and volume
     
  • the blood component producer’s name*
     
  • a unique pool or batch number or the donation number of all contributing units*
     
  • the ABO group*
     
  • the RhD group stated as positive or negative*
     
  • the date of collection
     
  • the expiry date of the frozen component*
     
  • the temperature of storage
     
  • the blood pack lot number*
     
  • a warning that the component must be used within 4 hours of thawing
     
  • the name, composition and volume of anticoagulant.

In addition, the following statements should be made:

INSTRUCTION

Always check patient/component compatibility/identity

Inspect pack and contents for signs of deterioration or damage

Risk of adverse reaction/infection, including vCJD

7.18.3: Storage

For general guidelines, see section 6.7.

  • The component should be stored at a core temperature of –25°C or below for a maximum of 36 months.
     
  • Although a storage temperature below –25°C improves the preservation of labile coagulation factors, lower temperatures increase the fragility of plastic. Particular care must be taken when handling such packs.
     
  • The component should be thawed in a waterbath or other equipment designed for the purpose, within a vacuum-sealed overwrap bag according to a validated procedure. The optimal temperature at which the component should be thawed is 37°C; temperatures between 33°C and 37°C are acceptable.
     
  • Protocols must be in place to ensure that the equipment is cleaned daily and maintained to minimise the risk of bacterial contamination. After thawing, the content should be inspected to ensure that no insoluble cryoprecipitate is visible and that the container is intact.
     
  • Once thawed, the component must not be refrozen and should be transfused as soon as possible. If delay is unavoidable, the component should be stored at ambient temperature and used within 4 hours.

7.18.4: Testing

In addition to the mandatory and other tests required for blood donations described in Annex 4, and leucocyte counting (see sections 6.3 and 7.1), a minimum of 75% of those components tested for the parameters shown at Table 7.15 shall meet the specified values.

Table 7.15 Cryoprecipitate Pooled, Leucocyte Depleted – additional tests

Parameter Frequency of test Specification

Volume

1% or as determined by statistical process control
(if ≤10 components produced per month then test every available component)

100–250 mL

Fibrinogen

Refer to Technical information (section 17.18.1) above

≥700 mg/unit

FVIII:C

≥350 IU/unit

Leucocyte count

As per sections 6.3 and 7.1

<1 × 106/unit* in the starting component

* Pre-freeze methods validated for counting low numbers of leucocytes must be used

7.18.5: Transportation

For general guidelines, see section 6.11.

Every effort should be made to maintain the core storage temperature during transportation. Unless the component is to be thawed and used straightaway it should be transferred immediately to storage at the recommended temperature.